The average one-year price target for Citius Pharmaceuticals (NasdaqCM:CTXR) has been revised to $6.12 / share. This is an increase of 20.00% from the prior estimate of $5.10 dated April 25, 2026. The ...

The jump in price for CTXR stock comes alongside an increase in trading. As of this writing, more than 84 million shares of the stock have changed hands. For some context, the company’s daily average ...

View Citius Pharmaceuticals Inc CTXR stock quote prices, financial information, real-time forecasts, and company news from CNN.

With an upside potential of 843.40%, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 18, H.C. Wainwright analyst ...

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) shares jumped 22.12% in after-hours trading to $1.27 on Tuesday, following the company’s fiscal year 2025 business update and the commercial launch of its ...

Fintel reports that on December 30, 2024, D. Boral Capital upgraded their outlook for Citius Pharmaceuticals (NasdaqCM:CTXR) from Hold to Buy. As of December 23, 2024, the average one-year price ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Citius Pharmaceuticals Inc. Annual cash flow by MarketWatch. View CTXR net cash flow, operating cash flow, operating expenses and cash dividends.